NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report published on Saturday. The firm issued a hold rating on the stock.

NovaBay Pharmaceuticals Price Performance

Shares of NBY stock opened at $0.78 on Friday. NovaBay Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $12.08. The firm has a market capitalization of $3.81 million, a price-to-earnings ratio of -0.01 and a beta of 0.73. The business has a 50 day simple moving average of $0.62 and a 200 day simple moving average of $1.65.

NovaBay Pharmaceuticals (NYSE:NBY) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($1.37) EPS for the quarter. NovaBay Pharmaceuticals had a negative net margin of 102.72% and a negative return on equity of 744.33%. The business had revenue of $2.40 million for the quarter. On average, equities analysts anticipate that NovaBay Pharmaceuticals will post -1.41 EPS for the current fiscal year.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.